Nucleix
7 known investors
Nucleix develops liquid biopsy and molecular diagnostic tests for early cancer detection, including its Bladder EpiCheck test for bladder and upper tract urinary cancer and a blood test in development for early-stage lung cancer. Its products are used by medical centers, laboratories, and healthcare systems, with offerings CE-marked in Europe and FDA 510(k) cleared in the United States.
BiotechHealthtechMedical Devices
Investors · 7
In the news
Frequently asked questions
- What does Nucleix do?
- Nucleix develops liquid biopsy and molecular diagnostic tests for early cancer detection, including its Bladder EpiCheck test for bladder and upper tract urinary cancer and a blood test in development for early-stage lung cancer. Its products are used by medical centers, laboratories, and healthcare systems, with offerings CE-marked in Europe and FDA 510(k) cleared in the United States.
- Who are Nucleix's investors?
- Nucleix's investors include Gefen Capital, OrbiMed, RA Capital, BlackRock, Lilly Asia Ventures, LYFE Capital, Sands Capital Ventures.